CRVS - コルバス・ファ―マシュ―ティカルズ (Corvus Pharmaceuticals Inc.) コルバス・ファ―マシュ―ティカルズ

 CRVSのチャート


 CRVSの企業情報

symbol CRVS
会社名 Corvus Pharmaceuticals Inc (コルバス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 コーバス・ファーマスーティカル(Corvus Pharmaceuticals Inc.)は臨床段階のバイオ医薬品会社である。同社は免疫腫瘍療法の開発と商品化に従事する。同社は免疫チェックポイントを阻止し、免疫T細胞を再プログラミングする薬物と抗体を開発する。同社は4つの免疫腫瘍学プログラムのパイプラインがあり、そのうち3つは免疫応答を調節するアデノシン - 癌軸に焦点を当てる。同社のリード製品候補であるCPI-444は免疫チェックポイントであるアデノシンに対するA2A受容体の経口・小分子アンタゴニストである。他の製品にはモノクローナル抗CD73抗体であるアデノシン産生阻害剤、アデノシンA2Bアンタゴニスト及びインターロイキン-2(IL-2)誘導性T細胞キナーゼ(ITK)阻害剤を含む。   コルバス・ファ―マシュ―ティカルズは米国の臨床段階のバイオ医薬品企業。がん治療のための新薬の開発・商品化に注力する。主に、アデノシンの生産を阻害及び抑制することで、免疫反応の調整を促す免疫腫瘍学のパイプラインを構築。また、T細胞の活性化と分化を調節するための治療薬も開発中。本社はカリフォルニア州。   Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The company focuses on disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.
本社所在地 863 Mitten Road Suite 102 Burlingame CA 94010 USA
代表者氏名 Richard A. Miller リチャード・A・ミラー
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 650-900-4520
設立年月日 41640
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 55人
url www.corvuspharma.com
nasdaq_url https://www.nasdaq.com/symbol/crvs
adr_tso
EBITDA EBITDA(百万ドル) -51.16600
終値(lastsale) 8.58
時価総額(marketcap) 250517613.06
時価総額 時価総額(百万ドル) 248.47380
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 115.24880
当期純利益 当期純利益(百万ドル) -50.57800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Corvus Pharmaceuticals Inc revenues was not reported. Net loss decreased 16% to $25.9M. Lower net loss reflects Research and development - Balancing val decrease of 18% to $20.3M (expense) General and administrative - Balancing decrease of 18% to $3.1M (expense) Interest income increase from $374K to $970K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.52 to -$1.03.

 CRVSのテクニカル分析


 CRVSのニュース

   What Makes Corvus (CRVS) a New Buy Stock  2020/05/20 16:00:06 Zacks Investment Research
Corvus (CRVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   Sign up as a Red Cross volunteer during coronavirus crisis  2020/03/26 16:34:42 Cornwall Live
So far more than 3,300 people across the region have joined the British Red Cross by signing-up to become community reserve volunteers (CRVs)
   The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings  2020/03/13 11:52:53 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.
   Corvus Pharmaceuticals : to Present Preclinical and Early Clinical Data from the Phase 1/1b Trial with CPI-818 at the American Society of Hematology (ASH) Annual Meeting | MarketScreener  2019/11/07 13:45:39 MarketScreener
BURLINGAME, Calif., Nov. 07, 2019 -- Corvus Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted… | November 7, 2019
   The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering  2019/10/04 11:32:50 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week lows on Oct. 3) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed on Thursday) Viela Bio Incn (NASDAQ: VIE ) (IPOed on Thursday) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 3) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) bluebird bio Inc . (NASDAQ: BLUE ) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) DelMar Pharmaceuticals Inc (NASDAQ: DMP ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Erytech Pharma SA (NASDAQ: ERYP ) Frequency Therapeutics Inc (NASDAQ: FREQ )(IPOed on Thursday) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Jaguar Health Inc (NASDAQ: JAGX ) Karuna Therapeutics Inc (NASDAQ: KRTX ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Neuralstem, Inc. (NASDAQ: CUR ) Obseva SA (NASDAQ: OBSV ) Onconova Therapeutics Inc (NASDAQ: ONTX ) RA Medical Systems Inc (NYSE: RMED ) Sierra Oncology Inc (NASDAQ: SRRA ) Titan Pharmaceuticals, Inc. (NASDAQ: TTNP ) Trinity Biotech plc (NASDAQ: TRIB ) Viveve Medical Inc (NASDAQ: VIVE ) Stocks In Focus Arbutus Halts Hepatitis B Drug Study Arbutus Biopharma Corp (NASDAQ: ABUS ) decided to discontinue the development of AB-506, an oral capsid inhibitor, which was being evaluated in a Phase 1a/1b trial for the treatment …
   The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings  2020/03/13 11:52:53 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.
   Corvus Pharmaceuticals : to Present Preclinical and Early Clinical Data from the Phase 1/1b Trial with CPI-818 at the American Society of Hematology (ASH) Annual Meeting | MarketScreener  2019/11/07 13:45:39 MarketScreener
BURLINGAME, Calif., Nov. 07, 2019 -- Corvus Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted… | November 7, 2019
   The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering  2019/10/04 11:32:50 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week lows on Oct. 3) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed on Thursday) Viela Bio Incn (NASDAQ: VIE ) (IPOed on Thursday) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 3) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) bluebird bio Inc . (NASDAQ: BLUE ) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) DelMar Pharmaceuticals Inc (NASDAQ: DMP ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Erytech Pharma SA (NASDAQ: ERYP ) Frequency Therapeutics Inc (NASDAQ: FREQ )(IPOed on Thursday) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Jaguar Health Inc (NASDAQ: JAGX ) Karuna Therapeutics Inc (NASDAQ: KRTX ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Neuralstem, Inc. (NASDAQ: CUR ) Obseva SA (NASDAQ: OBSV ) Onconova Therapeutics Inc (NASDAQ: ONTX ) RA Medical Systems Inc (NYSE: RMED ) Sierra Oncology Inc (NASDAQ: SRRA ) Titan Pharmaceuticals, Inc. (NASDAQ: TTNP ) Trinity Biotech plc (NASDAQ: TRIB ) Viveve Medical Inc (NASDAQ: VIVE ) Stocks In Focus Arbutus Halts Hepatitis B Drug Study Arbutus Biopharma Corp (NASDAQ: ABUS ) decided to discontinue the development of AB-506, an oral capsid inhibitor, which was being evaluated in a Phase 1a/1b trial for the treatment …
   The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave  2019/09/27 11:56:12 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 26.) AstraZeneca plc (NYSE: AZN ) GlaxoSmithKline plc (NYSE: GSK ) Sanofi SA (NASDAQ: SNY ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks that hit 52-week lows Sept. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Aduro BioTech Inc (NASDAQ: ADRO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) AnaptysBio Inc (NASDAQ: ANAB ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) AzurRx BioPharma Inc (NASDAQ: AZRX ) Bellerophon Therapeutics Inc (NASDAQ: BLPH ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (announced submission of clinical trial application to U.K. regulators for its investigational therapy for phenylketonuria) BioNano Genomics Inc (NASDAQ: BNGO ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Calithera Biosciences Inc (NASDAQ: CALA ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) CytomX Therapeutics Inc (NASDAQ: CTMX ) strong>DiaMedica Therapeutics Inc (NASDAQ: DMAC ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) ( announced mid-stage results of NASH treatment candidate) Enochian Biosciences Inc (NASDAQ: ENOB ) Erytech Pharma SA (NASDAQ: ERYP ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Gritstone Oncology Inc (NASDAQ: GRTS ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) IGM Biosciences Inc (NASDAQ: IGMS ) (initial public offering on Sept.
   Need To Know: Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Insiders Have Been Buying Shares  2019/07/03 15:14:59 Yahoo Finance
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that…
   The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings  2020/03/13 11:52:53 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.
   Corvus Pharmaceuticals : to Present Preclinical and Early Clinical Data from the Phase 1/1b Trial with CPI-818 at the American Society of Hematology (ASH) Annual Meeting | MarketScreener  2019/11/07 13:45:39 MarketScreener
BURLINGAME, Calif., Nov. 07, 2019 -- Corvus Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted… | November 7, 2019
   The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering  2019/10/04 11:32:50 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week lows on Oct. 3) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed on Thursday) Viela Bio Incn (NASDAQ: VIE ) (IPOed on Thursday) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 3) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) bluebird bio Inc . (NASDAQ: BLUE ) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) DelMar Pharmaceuticals Inc (NASDAQ: DMP ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Erytech Pharma SA (NASDAQ: ERYP ) Frequency Therapeutics Inc (NASDAQ: FREQ )(IPOed on Thursday) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Jaguar Health Inc (NASDAQ: JAGX ) Karuna Therapeutics Inc (NASDAQ: KRTX ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Neuralstem, Inc. (NASDAQ: CUR ) Obseva SA (NASDAQ: OBSV ) Onconova Therapeutics Inc (NASDAQ: ONTX ) RA Medical Systems Inc (NYSE: RMED ) Sierra Oncology Inc (NASDAQ: SRRA ) Titan Pharmaceuticals, Inc. (NASDAQ: TTNP ) Trinity Biotech plc (NASDAQ: TRIB ) Viveve Medical Inc (NASDAQ: VIVE ) Stocks In Focus Arbutus Halts Hepatitis B Drug Study Arbutus Biopharma Corp (NASDAQ: ABUS ) decided to discontinue the development of AB-506, an oral capsid inhibitor, which was being evaluated in a Phase 1a/1b trial for the treatment …
   The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave  2019/09/27 11:56:12 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 26.) AstraZeneca plc (NYSE: AZN ) GlaxoSmithKline plc (NYSE: GSK ) Sanofi SA (NASDAQ: SNY ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks that hit 52-week lows Sept. 26.) ABIOMED, Inc. (NASDAQ: ABMD ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Aduro BioTech Inc (NASDAQ: ADRO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) AnaptysBio Inc (NASDAQ: ANAB ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) AzurRx BioPharma Inc (NASDAQ: AZRX ) Bellerophon Therapeutics Inc (NASDAQ: BLPH ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) (announced submission of clinical trial application to U.K. regulators for its investigational therapy for phenylketonuria) BioNano Genomics Inc (NASDAQ: BNGO ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Calithera Biosciences Inc (NASDAQ: CALA ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) CytomX Therapeutics Inc (NASDAQ: CTMX ) strong>DiaMedica Therapeutics Inc (NASDAQ: DMAC ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) ( announced mid-stage results of NASH treatment candidate) Enochian Biosciences Inc (NASDAQ: ENOB ) Erytech Pharma SA (NASDAQ: ERYP ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Gritstone Oncology Inc (NASDAQ: GRTS ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) IGM Biosciences Inc (NASDAQ: IGMS ) (initial public offering on Sept.
   Need To Know: Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Insiders Have Been Buying Shares  2019/07/03 15:14:59 Yahoo Finance
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 コルバス・ファ―マシュ―ティカルズ CRVS Corvus Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)